Photoacoustic (PA) imaging is an emerging non-invasive diagnostic modality with many potential clinical applications in oncology, rheumatology and the cardiovascular field. For this purpose, there is a high demand for exogenous contrast agents with high absorption coefficients in the optical window for tissue imaging, i.e. the near infrared (NIR) range between 680 and 950 nm. We herein report the photoacoustic properties of quinone-fused porphyrins inserted with different transition metals as new highly promising candidates. These dyes exhibit intense NIR absorption, a lack of fluorescence emission, and PA sensitivity in concentrations below 3 nmol mL⁻¹. In this context, the highest PA signal was obtained with a Zn(II) inserted dye. Furthermore, this dye was stable in blood serum and free thiol solution and exhibited negligible cell toxicity. Additionally, the Zn(II) probe could be detected with an up to 3.2 fold higher PA intensity compared to the clinically most commonly used PA agent, ICG. Thus, further exploration of the ‘quinone-fusing’ approach to other chromophores may be an efficient way to generate highly potent PA agents that do not fluoresce and shift their absorption into the NIR range.

Photoacoustic imaging (PAI) is increasingly employed in (pre‐) clinical research, thus, development of suitable contrast agents, in particular fluorescence‐quenched chromophores, for PAI is of high importance. Small molecule dyes are appropriate due to favorable circulation, excretion properties, and ease of conjugation to targeting moieties. The BODIPY chromophores have been widely used in bioimaging, yet they are not ideal for PAI due to high fluorescence. Hence, here nonfluorescent BODIPY are designed by 1H‐pyrrole conjugation (PyBODIPY) to apply as probes for PAI. The PyBODIPYs exhibit absorption maxima up to 800 nm, and PA signal could be detected in concentrations of 1 nmol mL⁻¹ and 35 pmol mm⁻³, by tube and tissue phantom, respectively. In addition to nonfluorescent, PyBODIPYs are non‐phototoxic, photostable, and show high molar extinction coefficients, as well as inertness toward nucleophilic addition. PyBODIPYs are modified with PEG‐400, to improve aqueous solubility and to enable in vivo imaging. Thus, PyBODIPY is an attractive small molecule to use as PA contrast agent, which could be coupled to targeting ligands for in vivo use. In addition, 1H‐pyrrole conjugation might be applied to the design of novel near‐infrared ranged quenchers suitable for PAI, and promote the development of probes for clinical translation.